Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levodopa-induced dyskinesias.

Giovanni Fabbrini1, Jonathan M Brotchie2, Francisco Grandas3

  • 1Department of Neurological Sciences University of Rome "La Sapienza", Rome, Italy.

Movement Disorders : Official Journal of the Movement Disorder Society
|April 13, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in Saccadic Hypometria over Time to Monitor Parkinson's Disease Progression.

Pharmaceutical medicine·2026
Same author

Loneliness predicts worse Parkinsonism: a longitudinal, community-based, clinical-pathological study.

NPJ Parkinson's disease·2026
Same author

Prebiotic intervention changes host and microbe proteomes in plasma extracellular vesicles of Parkinson's disease.

Scientific reports·2026
Same author

Offering and acceptance of plasma p-tau for the diagnosis of Alzheimer's disease: Results and insights from usual practice.

Journal of Alzheimer's disease : JAD·2026
Same author

Symptom-Oriented, Connectome-Informed Deep Brain Stimulation for Asymmetric Dystonic Tremor: Unilateral Ventral Intermediate Nucleus (VIM) DBS Targeting a Tremor-Dominant Network.

Journal of clinical medicine·2026
Same author

Alphonse Daudet's Description of Jean-Martin Charcot: A Perception That Blends Medicine, Literature, and Society.

Neurology·2026
Same journal

Gene Therapy for Amino Acid Decarboxylase Deficiency: Clinical and Imaging Outcomes in a French Cohort.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Alzheimer's Disease Cerebrospinal Fluid Biomarkers Predict Survival in Progressive Supranuclear Palsy.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Hyperhomocysteinemia and Vitamin B Deficiency as Potential Aggravating Factors in Huntington's Disease: A Prospective Monocentric Study.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Longitudinal Dynamics of Polyglutamine-Expanded ATXN3 in Biofluids of Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Putamen Structural-Functional Decoupling as an Early-Stage Candidate Imaging Marker for Motor Severity in Spinocerebellar Ataxia Type 3.

Movement disorders : official journal of the Movement Disorder Society·2026
Same journal

Melanopsin-Mediated Post-Illumination Pupillary Response in Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder and Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
See all related articles

Levodopa-induced dyskinesias (LID) are common Parkinson's disease complications. This review details LID

Area of Science:

  • Neurology
  • Movement Disorders
  • Pharmacology

Background:

  • Levodopa-induced dyskinesias (LID) are frequent and challenging complications in Parkinson's disease management.
  • Understanding LID's clinical presentations, pathophysiology, and treatment is crucial for patient care.

Purpose of the Study:

  • To review the clinical features, classification, pathophysiology, and management strategies for Levodopa-induced dyskinesias (LID).
  • To explore potential therapeutic targets beyond current dopaminergic adjustments.

Main Methods:

  • Literature review focusing on clinical syndromes, basal ganglia circuitry, and neurochemical pathways implicated in LID.
  • Analysis of current and emerging pharmacological interventions and rating scales for dyskinesia.

Related Experiment Videos

Main Results:

  • LID presents as OFF-period dystonia, peak-dose dyskinesia, and diphasic dyskinesia, complicating treatment.
  • Direct striatal output pathway overactivity is a key pathophysiological feature.
  • Amantadine is the only drug with evidence for dyskinesia efficacy; numerous other targets are under investigation.

Conclusions:

  • Effective management of LID requires addressing its diverse clinical forms and underlying pathophysiology.
  • Future therapies may target glutamatergic, GABAergic, and other neurotransmitter systems.
  • Development of new, validated rating scales is essential for assessing LID severity and treatment outcomes.